April 07, 2021
Video
As hematology and oncology pharmacists have become increasingly essential members of the care team, new investigational drugs could have a significant impact on the treatment landscape.
April 01, 2021
Article
Isatuximab in combination with carfilzomib and dexamethasone reduced the risk of disease progression or death by 45% versus standard of care alone.
March 31, 2021
Although pediatric patients represent a small portion of total acute myeloid leukemia cases, clinicians said there is a critical need for more effective therapies in this population.
March 30, 2021
Anti-inflammatory therapies could be effective at preventing heart disease in patients with clonal hematopoiesis, a common age-related blood condition, according to a new study published in Nature.
March 29, 2021
In a clinical trial of idecabtagene vicleucel in multiple myeloma, the overall response rate for the efficacy evaluable population was 72%, and 28% of participants achieved a stringent complete response.
March 09, 2021
Teclistamab showed promising clinical activity and a tolerable safety profile in patients with relapsed/refractory multiple myeloma.
March 08, 2021
The FDA has approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.
March 03, 2021
There are specific treatment options patients may qualify for depending on the cytogenetic or molecular abnormality detected.
March 01, 2021
Investigators recommended avoiding risk factors such as smoking and switching to a transdermal administration route for testosterone.
The FDA has approved melphalan flufenamide (Pepaxto; melflufen) for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.
